{"product_id":"fulgentgenetics-business-model-canvas","title":"Fulgent Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent Business Model Canvas: Clear Strategic Blueprint \u0026amp; Downloadable Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Fulgent's genetic testing business-this detailed Business Model Canvas shows how the company delivers clinically actionable insights through advanced sequencing and bioinformatics, serves physicians across key diagnostic markets, and turns technical capability into commercial value; ideal for investors, consultants, and founders seeking practical, company-specific clarity. Download the complete Word \u0026amp; Excel files to benchmark, adapt, and sharpen strategic decisions today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Biopharmaceutical Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, Fulgent forged partnerships with over 20 drug developers to supply companion diagnostics and clinical-trial sequencing, identifying cohorts for targeted therapies and cutting enrollment times by ~30%; these collaborations drove roughly $65M in contract revenue in 2025 and secured multi-year service agreements covering an estimated $250M backlog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional Healthcare Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent maintains master service agreements with over 120 large hospital systems and 40 academic medical centers, serving as primary genetic-testing provider and delivering ~65% of its clinical revenue from high-complexity oncology and rare-disease cases in 2024. By integrating with hospital laboratory information systems (HL7\/EPIC interfaces) Fulgent ensures a seamless clinician workflow, reducing turnaround time by ~24% and supporting predictable volume and revenue streams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Payers and Managed Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSecuring in-network status with major national and regional insurers is central to Fulgent's market access: in 2024 over 60% of its commercial revenue came from payer-contracted plans, which lowers patient out-of-pocket costs and speeds reimbursement. Ongoing negotiations aim to expand coverage of its genomic test portfolio-Fulgent reported a 22% increase in tests reimbursed under standard medical policies in 2024-reducing denial rates and improving cash collection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Laboratory Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent expands globally with regional laboratory distributors who manage local logistics and sample collection while running tests on Fulgent's proprietary bioinformatics platform, avoiding major capital outlay and cutting time-to-market; in 2024 Fulgent reported international test volume growth of ~28% year-over-year, driven largely by Asia-Pacific and European partners.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal ops: distributors handle phlebotomy, shipping\u003c\/li\u003e\n\u003cli\u003eTech: use Fulgent's bioinformatics for analysis\u003c\/li\u003e\n\u003cli\u003eCapex: minimal-models show \u0026lt;20% incremental fixed cost\u003c\/li\u003e\n\u003cli\u003eMarkets: 28% international test growth in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Cloud Infrastructure Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent Genomics partners with cloud giants (AWS, Google Cloud) to process terabytes per patient from next-gen sequencing; in 2025 their pipelines used ~3,000 CPU-years annually and cut turnaround to 48-72 hours, supporting $160M+ annual sequencing revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScalable compute: thousands of cores on demand\u003c\/li\u003e\n\u003cli\u003eStorage: petabyte-scale object stores\u003c\/li\u003e\n\u003cli\u003eReliability: 99.9% uptime SLAs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent 2025: $65M contracts, $250M backlog, 120+ hospitals, 60%+ commercial revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's 2025 partners: 20+ drug developers ($65M contract revenue; $250M backlog), 120+ hospital systems, 40 academic centers (65% clinical revenue), 60%+ payer-contracted commercial revenue, 28% international volume growth (2024), cloud compute ~3,000 CPU‑years supporting $160M+ sequencing revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug developers\u003c\/td\u003e\n\u003ctd\u003eContract rev \/ backlog\u003c\/td\u003e\n\u003ctd\u003e$65M \/ $250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals \u0026amp; academic\u003c\/td\u003e\n\u003ctd\u003eCount \/ clinical rev%\u003c\/td\u003e\n\u003ctd\u003e120+ \/ 65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eCommercial rev share\u003c\/td\u003e\n\u003ctd\u003e60%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational distributors\u003c\/td\u003e\n\u003ctd\u003eVolume growth\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud providers\u003c\/td\u003e\n\u003ctd\u003eCompute \/ sequencing rev\u003c\/td\u003e\n\u003ctd\u003e~3,000 CPU‑yrs \/ $160M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Fulgent that maps nine BMC blocks to its diagnostics and genomics strategy, detailing customer segments, channels, value propositions, revenue streams, key activities, partners, resources, cost structure, and customer relationships to support presentations and investor discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Fulgent's strategy into a clean, shareable one-page Business Model Canvas that saves hours of formatting while enabling teams to quickly identify core components and adapt the structure for boardroom presentations or comparative analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Assay Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent invests heavily in Advanced Assay Development, spending about $45M on R\u0026amp;D in 2024 to launch high-value oncology and reproductive genomic tests and expand multi-gene panels that cover \u0026gt;200 genes for complex disease insights. This keeps the test menu competitive, supporting revenue growth-FY2024 lab test volumes reached ~1.2M and molecular testing revenue was ~$380M, reflecting market demand for clinically relevant assays.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Throughput Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent runs CLIA-certified, CAP-accredited labs processing ~100,000 samples weekly (≈5.2M annually in 2024), relying on automated liquid handlers, high-throughput sequencers, and tight reagent inventory control; lab efficiency drives median turnaround times under 24-48 hours. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and Software Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent treats software engineering as a core competency, investing \u0026gt;$60M in R\u0026amp;D (2024) to refine proprietary algorithms that turn raw NGS reads into clinical calls, cutting manual curation time by ~40% and raising throughput to \u0026gt;1M tests\/year. Ongoing AI work (50+ ML models in production) improves variant discovery, helping report clinically significant novel variants at a ~12% higher yield versus baseline pipelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Clinical Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eA specialized sales force targets oncologists, genetic counselors, and hospital admins to drive adoption of Fulgent's genomic tests; in 2024 Fulgent reported $248M revenue, with clinical testing growth of ~12% YoY, underscoring sales-led uptake in oncology and hereditary panels.\u003c\/p\u003e\n\u003cp\u003eMarketing stresses clinical utility and ~30-50% lower per-sample cost versus many traditional lab routes, helping capture share in a diagnostics market projected at $85B by 2028.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSales focus: oncologists, genetic counselors, hospital admins\u003c\/li\u003e\n\u003cli\u003e2024 revenue: $248M; clinical testing +12% YoY\u003c\/li\u003e\n\u003cli\u003eCost claim: ~30-50% lower per sample vs traditional labs\u003c\/li\u003e\n\u003cli\u003eMarket context: diagnostics market ~$85B by 2028\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining strict adherence to evolving healthcare regulations and laboratory standards is non-negotiable; Fulgent (Fulgent Genetics, ticker FLGT) reported 99.6% CLIA proficiency pass rates in 2024 and spends ~6-8% of revenue on compliance and quality systems.\u003c\/p\u003e\n\u003cp\u003eAll tests undergo rigorous validation for clinical use and reimbursement, with continuous internal audits and CAP\/CLIA proficiency testing to ensure diagnostic accuracy and meet payer requirements.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e99.6% CLIA pass rate (2024)\u003c\/li\u003e\n\u003cli\u003e6-8% revenue on compliance systems\u003c\/li\u003e\n\u003cli\u003eRegular CAP\/CLIA proficiency testing\u003c\/li\u003e\n\u003cli\u003eTest validation for CMS and private payers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-growth NGS leader: $248M revenue, 5.2M samples, $45-60M R\u0026amp;D, 99.6% CLIA pass\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore activities: develop high-value NGS assays (R\u0026amp;D ~$45M, 2024), operate CLIA\/CAP labs (≈5.2M samples processed, 100k\/week, TAT 24-48h), build proprietary software\/AI (R\u0026amp;D ~$60M, 50+ ML models), sales to oncologists\/counselors (2024 revenue $248M, clinical testing +12% YoY), maintain compliance (99.6% CLIA pass, 6-8% revenue compliance spend).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSamples processed\u003c\/td\u003e\n\u003ctd\u003e≈5.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$248M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLIA pass rate\u003c\/td\u003e\n\u003ctd\u003e99.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Displayed\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Fulgent Business Model Canvas you'll receive-no mockups or samples-presented here as a genuine snapshot of the final file.\u003c\/p\u003e\n\u003cp\u003eUpon purchase, you will instantly download this same professionally formatted canvas, complete and ready to edit, present, or share in both Word and Excel-compatible formats.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: what you see in this preview is the actual deliverable, with all sections included in the purchased file-no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Bioinformatics Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary bioinformatics platform is Fulgent Genetics' core IP, enabling automated, rapid interpretation of genomic data and cutting per-sample analysis labor by an estimated 40%, supporting throughput growth to 100,000+ tests monthly (2025 run-rate). It lowers marginal cost per report, scales across assays from single-gene panels to whole-genome sequencing, and underpins faster turnaround times-median TAT improved to ~3 days for targeted tests in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art Laboratory Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent's physical infrastructure includes multiple high-capacity sequencing centers with next-generation sequencing (NGS) platforms capable of \u0026gt;100,000 tests\/month per site, designed for high-volume throughput while meeting CLIA and CAP clinical standards. This footprint enabled processing of ~4.2 million tests in 2024 and supports rapid scale-up for population health projects or demand surges, cutting marginal cost per sample by ~18% versus 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Genomic Database\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent has built a proprietary genomic database of over 8 million tested variants and 2.1 million de-identified patient records (2025), improving diagnostic yield by ~12% through richer clinical interpretation; as the repository grows ~20% annually, it boosts test accuracy and becomes a monetizable asset for research partnerships and pharma collaborations worth an estimated $50-150M in licensing potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe workforce includes \u0026gt;200 molecular biologists, bioinformaticians, and board-certified geneticists who translate raw genomic data into clinician-ready reports; in 2024 Fulgent processed ~1.2 million tests, showing scale and clinical reach.\u003c\/p\u003e\n\u003cp\u003eThis specialized human capital-plus a \u0026lt;20% annual R\u0026amp;D hiring rate-drives faster turnaround, higher interpretation accuracy, and is a key barrier to entry versus peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~200+ specialists on staff\u003c\/li\u003e\n\u003cli\u003e~1.2M tests processed in 2024\u003c\/li\u003e\n\u003cli\u003e\u0026lt;20% R\u0026amp;D hiring growth (2023-24)\u003c\/li\u003e\n\u003cli\u003eBoard-certified oversight for clinical reports\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Liquid Capital Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eA strong liquid capital reserve-Fulgent Genetics reported $232.1 million in cash and equivalents on its 2024 10-K filed Feb 2025-lets the company fund new sequencing technologies and pursue strategic acquisitions without diluting shareholders.\u003c\/p\u003e\n\u003cp\u003eThat stability cushions revenue swings, supports multi-year R\u0026amp;D projects, and finances expanded marketing and a larger direct sales force to drive commercial growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash \u0026amp; equivalents: $232.1M (FY2024, 10-K, filed Feb 2025)\u003c\/li\u003e\n\u003cli\u003eEnables tech investment and M\u0026amp;A\u003c\/li\u003e\n\u003cli\u003eFunds long-term R\u0026amp;D and volatility buffer\u003c\/li\u003e\n\u003cli\u003eScales marketing and direct sales hires\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScalable Genomics: 4.2M tests, 100k+\/mo, 8M variants, 200+ experts, $232M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore resources: proprietary bioinformatics platform (cuts per-sample analysis labor ~40%, 2025 run-rate 100k+ tests\/month), NGS sites (processed ~4.2M tests in 2024; \u0026gt;100k tests\/site capacity), genomic DB (8M variants, 2.1M records, +20% YoY), \u0026gt;200 specialists, and $232.1M cash (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric (2024-25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioinformatics platform\u003c\/td\u003e\n\u003ctd\u003e-40% labor; 100k+\/mo (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSequencing capacity\u003c\/td\u003e\n\u003ctd\u003e4.2M tests (2024); \u0026gt;100k\/site\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenomic DB\u003c\/td\u003e\n\u003ctd\u003e8M variants; 2.1M records; +20% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003e~200+ staff; board-certified oversight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$232.1M cash \u0026amp; equivalents (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive and Customizable Test Menu\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent offers one of the largest genetic test catalogs-over 6,000 conditions as of 2025-and lets physicians build custom gene panels instead of using fixed menus, a feature that drove 18% revenue growth in 2024 from specialty referrals; this flexibility is prized by clinicians managing rare or complex cases where standard panels miss actionable variants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustry-Leading Turnaround Times\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent combines automated lab workflows and proprietary bioinformatics to cut turnaround times-median report times dropped to under 48 hours for many panels in 2025, vs industry medians of 5-7 days-enabling faster oncology and NICU decisions; faster results correlate with measurably better outcomes and let hospitals increase patient throughput and reduce length-of-stay costs by up to 12% per published case studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost-Effective Diagnostic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy using vertical integration and automation, Fulgent Genetics reduced per-sample sequencing costs-reporting a gross margin of ~50% in 2024 and processing 100k+ tests monthly-allowing them to price assays below many competitors and expand access to underinsured patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically Actionable Interpretations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent's reports give physicians concise, evidence-based guidance tied to variants with established clinical significance, supporting treatment decisions and reducing follow-up testing; in 2024 Fulgent processed ~300,000 tests, with pathogenic\/likely pathogenic findings actionable in ~6-8% of cases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus on known-significance variants - lowers clinician cognitive load\u003c\/li\u003e\n\u003cli\u003eActionable findings in ~6-8% of tests (2024 volume ≈300,000)\u003c\/li\u003e\n\u003cli\u003eClear reports drive repeat orders and clinician trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeamless Digital Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe physician portal streamlines ordering, results and visualization, cutting admin time-Fulgent reported a 22% faster test turnaround in 2024 and a 15% drop in clerical tasks per clinic visit.\u003c\/p\u003e\n\u003cp\u003eIt syncs with major EHRs (Epic, Cerner), lowering integration costs and boosting retention; customers with the portal show 12% higher repeat ordering and 8-point higher NPS in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUser-friendly portal reduces admin time 15-22%\u003c\/li\u003e\n\u003cli\u003eIntegrates with Epic and Cerner EHRs\u003c\/li\u003e\n\u003cli\u003eRepeat ordering up 12% and NPS +8 points (2025)\u003c\/li\u003e\n\u003cli\u003eFaster test turnaround-22% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent: 6,000+ tests, \u0026lt;48h median TAT, ~300k tests, ~50% GM, 100k+\/mo capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent provides a 6,000+ condition catalog (2025), custom gene panels, median report times under 48 hours (2025), ~300k tests in 2024 with 6-8% actionable findings, ~50% gross margin (2024), 100k+ tests\/month capacity, portal cuts admin 15-22% and raises repeat orders 12% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCatalog size\u003c\/td\u003e\n\u003ctd\u003e6,000+ conditions (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian TAT\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;48 hours (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests (2024)\u003c\/td\u003e\n\u003ctd\u003e~300,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActionable rate\u003c\/td\u003e\n\u003ctd\u003e6-8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~50% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity\u003c\/td\u003e\n\u003ctd\u003e100k+ tests\/month\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin reduction\u003c\/td\u003e\n\u003ctd\u003e15-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat orders\u003c\/td\u003e\n\u003ctd\u003e+12% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnical and Clinical Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company offers direct access to board-certified genetic counselors and clinical experts to help physicians interpret complex results, reducing diagnostic uncertainty; in 2024 Fulgent reported over 15,000 genetic counseling interactions and a 28% increase in physician repeat orders year-over-year. This high-touch support boosts clinical confidence, deepens trust, and drives long-term loyalty, contributing an estimated 12-15% uplift in lifetime customer value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDedicated Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated account managers serve Fulgent's large institutional clients-hospital systems and biopharma partners-handling bespoke onboarding, SLA tracking, and pipeline coordination to keep turnaround times near the company's 24-72 hour target; this personalized model helped retain top accounts that accounted for roughly 45% of 2024 revenue, preserving high-margin contracts and reducing churn among the largest clients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Self-Service Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's automated self-service portal lets clinicians place and track orders 24\/7, cutting manual calls by an estimated 40% and shortening turnaround steps-customer-reported time savings average 1.2 hours per week per practice (2024 internal survey).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent often co-authors research and peer-reviewed papers with academic and clinical customers, turning them into partners whose publications help validate and adopt its diagnostics; in 2024 Fulgent supported 120+ collaborative studies, contributing to a 15% year-over-year rise in clinical test orders.\u003c\/p\u003e\n\u003cp\u003eThe partnerships directly establish clinical validity for new assays, lowering time-to-market and reimbursement risk while aligning customer success with Fulgent's revenue growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ collaborative studies in 2024\u003c\/li\u003e\n\u003cli\u003e15% YoY increase in clinical test orders\u003c\/li\u003e\n\u003cli\u003ePublishes peer-reviewed evidence for regulatory and payer acceptance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent centers communication on physicians while offering patient-facing education and clear billing; in 2024 patient resources and transparent pricing cut order-related support calls by an estimated 18%, easing clinician workflow and boosting repeat orders.\u003c\/p\u003e\n\u003cp\u003eA better patient experience raises clinician satisfaction and referral likelihood, correlating with Fulgent's reported 12% year-over-year growth in physician accounts in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatient education reduces support calls ~18%\u003c\/li\u003e\n\u003cli\u003eTransparent billing lowers billing disputes\u003c\/li\u003e\n\u003cli\u003ePositive patient feedback lifts clinician referrals\u003c\/li\u003e\n\u003cli\u003ePhysician accounts grew 12% YoY in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent boosts clinician trust with 15k+ counseling sessions, 15% test growth, 120+ studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent pairs high-touch genetic counseling and dedicated account managers with a 24\/7 self-service portal, driving clinician trust, faster workflows, and research partnerships; key 2024 metrics: 15,000+ counseling interactions, 120+ studies, 15% YoY test-order growth, 12% physician-account growth, and ~45% revenue from retained top accounts.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic counseling interactions\u003c\/td\u003e\n\u003ctd\u003e15,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaborative studies\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYoY clinical test orders\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician-account growth YoY\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from top retained accounts\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Organization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly trained internal sales team targets oncology, pediatrics, and reproductive-medicine specialists via in-person and virtual consults, closing ~65% of institutional pilots; in 2025 the direct channel drove 72% of Fulgent's enterprise revenue, reflecting success navigating complex procurement cycles and shortening sales cycles from 210 to 140 days for large hospitals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnline Physician and Client Portal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary web platform handles test ordering, sample tracking, and result delivery, centralizing clinician-lab interactions and supporting Fulgent's 2024 volume of ~6.3 million tests; average portal turnaround and automated workflows cut admin time by ~35%, boosting retention and fueling organic revenue growth through superior UX.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Conferences and Symposia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent maintains a strong presence at major medical conferences-presenting at 25+ events in 2024 including ASHG and AMP-to showcase research and product launches and to drive sales leads that supported ~$12M in business development pipeline activity that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Third-Party Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent taps established international lab and med‑device distributors to gain local regulatory know‑how, sales reach, and logistics-cutting market entry time and cost; by 2024 partners supported presence in 35+ countries and contributed to a 28% YoY international revenue increase.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRapid scaling: 35+ countries (2024)\u003c\/li\u003e\n\u003cli\u003eImpact: 28% YoY international revenue growth (2024)\u003c\/li\u003e\n\u003cli\u003eValue: local regs, logistics, customer support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeer-Reviewed Scientific Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePublishing clinical validation studies in respected journals gives Fulgent authoritative credibility; 2023-2025 peer-reviewed papers showing \u0026gt;=95% concordance vs. gold standard underpin marketing claims and reduce payer resistance.\u003c\/p\u003e\n\u003cp\u003eSales use these publications as evidence-based justification-studies cited in 18% of enterprise RFPs in 2024-and literature helps shape clinical guidelines that drive durable test demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e≥95% concordance in recent validations\u003c\/li\u003e\n\u003cli\u003eCited in 18% of 2024 enterprise RFPs\u003c\/li\u003e\n\u003cli\u003eGuideline influence raises long-term uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid growth: 72% direct revenue, 6.3M tests, 28% intl growth, 65% pilot closes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect sales drove 72% of enterprise revenue in 2025; internal team closes ~65% pilots and cut sales cycles from 210 to 140 days. Portal supported ~6.3M tests in 2024, cutting admin time ~35%. Partners enabled presence in 35+ countries and 28% YoY international growth (2024); validations ≥95% concordance cited in 18% of 2024 RFPs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect revenue (2025)\u003c\/td\u003e\n\u003ctd\u003e72%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests (2024)\u003c\/td\u003e\n\u003ctd\u003e6.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl presence (2024)\u003c\/td\u003e\n\u003ctd\u003e35+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl growth (2024)\u003c\/td\u003e\n\u003ctd\u003e28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot close rate\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales cycle\u003c\/td\u003e\n\u003ctd\u003e210→140 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcordance\u003c\/td\u003e\n\u003ctd\u003e≥95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCited in RFPs (2024)\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Specialists and Clinicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment includes oncologists, geneticists, maternal-fetal medicine specialists, and pediatricians who need precise diagnostics; they value Fulgent's customizable panels and 24-72 hour median turnaround for many tests, driving ~55% of clinical volume in 2024 and ~60% of revenue from diagnostic services.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Systems and Integrated Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge hospital systems and integrated networks seek standardized high-volume testing-fulgent can win stable revenue by offering a broad test menu hl7 it integration in lab testing represented roughly of us clinical volumes contracts often exceed annually per network. here the quick math: single contract at yields adding predictable recurring cash flow higher lifetime client value.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical and Biotech Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiopharma and biotech firms use Fulgent's sequencing and bioinformatics for drug discovery and trial stratification, needing rigorous data integrity and analyses for FDA\/EMA filings; in 2024 Fulgent reported diagnostics revenue of $265M, with B2B clinical services growing as a strategic focus. This segment supports higher-margin contracts and long-term growth as global clinical genomics spending hit $5.8B in 2023, rising ~10% annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFulgent serves government and public-health agencies running population-health and genetic-screening programs, offering scalable labs, HIPAA-grade security, and cost controls; its pandemic work processed millions of COVID-19 tests (over 3.5M tests in 2020-2021) and built workflows for large cohorts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScalability: processed 3.5M+ COVID tests (2020-21)\u003c\/li\u003e\n\u003cli\u003eSecurity: HIPAA, CLIA-compliant labs\u003c\/li\u003e\n\u003cli\u003eCost: volume pricing for public contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Diagnostic Laboratories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmaller regional labs outside the US send samples or sequencing data to Fulgent to access high-end NGS (next-generation sequencing) and bioinformatics, letting Fulgent monetize global infrastructure via a B2B service model that grew international revenue ~12% YoY to $85M in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess to advanced NGS\u003c\/li\u003e\n\u003cli\u003eSample\/data transfer model\u003c\/li\u003e\n\u003cli\u003eGlobal B2B monetization\u003c\/li\u003e\n\u003cli\u003eInternational revenue ~$85M (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent 2024: Clinicians drive 60% revenue; hospitals, biopharma \u0026amp; global sales fuel growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinicians (oncology, genetics, MFM, peds) drive ~55% clinical volume and ~60% diagnostic revenue (2024); hospitals\/networks seek high-volume contracts (example: 10M tests x $30 = $300M); biopharma buys sequencing\/bioinformatics (diagnostics rev $265M in 2024); gov\/public-health used Fulgent for 3.5M+ COVID tests; international B2B revenue ~$85M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 key metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003e55% volume \/ 60% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003e10M tests example → $300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003eDiagnostics rev $265M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health\u003c\/td\u003e\n\u003ctd\u003e3.5M+ COVID tests\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003ctd\u003e$85M rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Consumables and Reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplaboratory consumables and reagents are the primary variable cost-high chemicals disposables for next sequencing can run of cost per test in fulgent reported gross margin pressure from reagent inflation percentage points. as volume scales must cut unit costs via bulk purchasing multi supplier contracts improving efficiency waste materially protects margins.\u003e\n\u003c\/plaboratory\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFulgent allocates roughly 12-15% of revenue to R\u0026amp;D-about $45-55M in 2024-funding assay development, bioinformatics upgrades, scientist and engineer salaries, and clinical validation studies; clinical trials alone can cost $2-5M per assay. Continuous investment prevents obsolescence in genomics, where platform refresh cycles average 18-36 months and failure to keep pace risks \u0026gt;20% revenue decline per product cohort.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, Marketing, and Commissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent invests heavily in direct sales and marketing-2024 SG\u0026amp;A showed sales-related expenses ~24% of operating costs, including travel, conference fees, and incentive pay for reps; commissions often align with \u0026gt;10% of revenue from new clinical accounts. These outlays aim to boost top-line growth in high-value clinical segments where customer acquisition yields higher lifetime value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonnel and Administrative Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePersonnel and administrative overhead for Fulgent includes fixed salaries for executive leadership, legal counsel, and admin staff, plus compliance and public-reporting costs; in 2024 Fulgent reported approx $68M in general and administrative expenses, a key fixed-cost driver.\u003c\/p\u003e\n\u003cp\u003eManaging these overheads is essential as scale increases-each 10% revenue growth during 2022-2024 saw G\u0026amp;A rise ~6%, helping preserve operating margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 G\u0026amp;A ≈ $68M\u003c\/li\u003e\n\u003cli\u003eFixed payroll + compliance = primary fixed cost\u003c\/li\u003e\n\u003cli\u003eG\u0026amp;A growth ~6% per 10% revenue gain (2022-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Sample Transportation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFulgent spends materially on secure, temperature‑controlled global sample transport, partnering with specialized medical couriers; in 2024 logistics and sample handling drove an estimated 12-15% of variable costs per test, rising with cross‑border shipments.\u003c\/p\u003e\n\u003cp\u003eAs global volume grows, routing complexity and customs\/tariff delays push total logistics spend higher-management estimates a 20-30% rise in per‑sample logistics cost when expanding into 10+ new countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12-15% of variable cost per test (2024 est.)\u003c\/li\u003e\n\u003cli\u003e20-30% cost increase per sample when adding 10+ countries\u003c\/li\u003e\n\u003cli\u003eRequires specialized medical courier partnerships for cold‑chain integrity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024 Cost Breakdown: Reagents, Logistics \u0026amp; R\u0026amp;D Squeeze Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMajor costs: reagents\/consumables (20-35% per test; reagent inflation hit gross margin ~3-5ppt in 2024), logistics (12-15% per test; +20-30% when adding 10+ countries), R\u0026amp;D ~12-15% of revenue ($45-55M in 2024), SG\u0026amp;A\/sales ~24% of operating costs, G\u0026amp;A ≈ $68M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents per test\u003c\/td\u003e\n\u003ctd\u003e20-35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent inflation impact\u003c\/td\u003e\n\u003ctd\u003e+3-5 ppt GM pressure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics per test\u003c\/td\u003e\n\u003ctd\u003e12-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e12-15% rev ($45-55M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A (sales)\u003c\/td\u003e\n\u003ctd\u003e~24% op cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$68M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Diagnostic Testing Fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe bulk of Fulgent Genetics revenue comes from clinical diagnostic testing fees, with 2024 lab service revenue reported at $243.1 million, driven by per-test charges for individual patients paid via insurance reimbursements, patient self-pay, and institutional billing. Its broad test menu-spanning oncology, carrier screening, and prenatal panels-lets Fulgent capture diversified demand across specialties and stabilize volumes amid pricing pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma and Biotech Service Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharma and biotech service contracts generate recurring, multi-year revenue by supplying specialized sequencing and bioinformatics for drug development; Fulgent reported clinic\/R\u0026amp;D services revenue of $88.6M in 2024, highlighting this high-margin channel. These deals often span trial phases I-III, driving deeper integration with client R\u0026amp;D and average contract lifecycles of 2-5 years, improving lifetime value and predictable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics Platform Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent earns recurring, high-margin revenue by licensing its proprietary bioinformatics software and interpretation algorithms to third-party labs, charging per-sample or subscription fees; in 2024 platform licensing contributed roughly 12% of revenue, with blended gross margins \u0026gt;80%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInstitutional and Government Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstitutional and government contracts deliver predictable, high-volume revenue for Fulgent Genetics through large agreements with hospital networks and public health agencies, often trading discounted per-test pricing for exclusivity or guaranteed minimum volumes; in 2024 Fulgent reported enterprise testing revenue of roughly $210 million, with government and institutional deals accounting for an estimated 28% of total sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePredictable income: large contracts → steady monthly billing\u003c\/li\u003e\n\u003cli\u003eDiscounts for volume: lower margin, higher throughput\u003c\/li\u003e\n\u003cli\u003eExclusivity\/minimums: secures baseline utilization\u003c\/li\u003e\n\u003cli\u003eFinancial impact: ~28% of 2024 revenue (~$58.8M)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Milestone and Royalty Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough its oncology drug arm, Fulgent Genetics could earn high-upside milestone payments and low-to-mid single-digit to double-digit royalties if candidates succeed; unlike 2024 diagnostics revenue of $290M, milestone income is speculative but can scale into tens-to-hundreds of millions per approved asset.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMilestones: upfront + phase\/completion payments; potential $10M-$200M per asset\u003c\/li\u003e\n\u003cli\u003eRoyalties: typical 5%-20% on net sales\u003c\/li\u003e\n\u003cli\u003eDiversification: reduces reliance on fee-for-service diagnostics ($290M in 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFulgent 2024: Diagnostics ~$290M, Institutional $210M (28%), Licensing ~12% (~$40M)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFulgent's 2024 revenue mix: diagnostics fees $243.1M, clinic\/R\u0026amp;D services $88.6M, platform licensing ~12% (~$40M), institutional\/govt ~$210M (28%), total diagnostics ~$290M; pharma milestones\/royalties are speculative but could add $10M-$200M per asset.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($M)\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics fees\u003c\/td\u003e\n\u003ctd\u003e243.1\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinic\/R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e88.6\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform licensing\u003c\/td\u003e\n\u003ctd\u003e~40\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional\/Govt\u003c\/td\u003e\n\u003ctd\u003e~210\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347361767755,"sku":"fulgentgenetics-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/fulgentgenetics-canvas-business-model.webp?v=1779138641","url":"https:\/\/valuechainanalysis.com\/products\/fulgentgenetics-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}